AgingResearch.NewsJoin free

Cambrian Bio

CompanyUnited States

Cambrian Bio develops 12 assets, the furthest in phase 1 (ATX-304 in obesity). Mostly small molecule and cell therapy acting on MTOR, AMPK signalling and lipid and ceramide metabolism; based in the United States.

12
Assets
Furthest stage
Phase 1
1
Grant
0
Trials
0
Signals

Pipeline

12

  • ATX-304

    Activates the AMPK network, increasing glucose uptake and mitochondrial respiration to raise metabolic rate.

    Phase 1, Small molecule, AMPK signalling, Lipid and ceramide metabolism, obesity, obesity associated diseases

  • ATX-30

    Activates the AMPK network.

    Human trials, cardiometabolic disease, obesity

  • CAM-1108

    Preclinical, rare cardiovascular diseases

9 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms7
  • People24
  • Signals1
  • Similar companies6

Intelligence